Mazdutide vs Semaglutide

Mazdutide wins for:

• Greater total weight/fat loss at similar dosing, especially in trials using ≥6mg weekly.
• Glucagon-mediated increase in metabolic rate and preferential visceral/hepatic fat reduction, making it a favorite for users with fatty liver, elevated ALT/AST, or post-oral-AAS cleanup.
• Lower risk of pronounced muscle loss vs semaglutide alone due to energy expenditure boost and less reliance on caloric restriction.

Semaglutide wins for:

• Side-effect manageability, with less pronounced nausea and GI complaints at comparable weight-loss doses, especially in lower (≤1mg) or microdose protocols.
• Decades of safety and sourcing track record, with mature generic and compounded supply chains.
• Fine control over appetite modulation (microdosing works well) and a wider user base, including high adherence and predictable tolerability for newcomers.

Pick Mazdutide if:

• The goal is maximum fat/weight loss in a single cycle and user is not side-effect sensitive.
• Hepatic fat, NAFLD risk, or elevated enzymes need correction (especially after aggressive cycles or prolonged orals).
• Semaglutide alone left results on the table, or lean mass loss was an issue.
• Appetite suppression alone hasn't moved the needle—active calorie burning is desired.
• Tolerability to dual agonists is known from trial run at lower doses.

Pick Semaglutide if:

• Top priority is appetite suppression with minimal GI or systemic side effects.
• The protocol calls for microdosing to gently manage hunger (0.1–1mg weekly), such as contest prep, post-blast cleanup, or indefinite cruise.
• Sourcing security and lowest price/availability risk are important—semaglutide is everywhere.
• Muscle sparing is controlled through aggressive stacking (AAS/TRT/GH), and GLP-1 monoagonism is sufficient.
• The user needs the largest safety/long-term outcome dataset and lowest unpredictability for first-time use.